Selective lesions of rabbit extraocular muscles injected with the anti-AChR immunotoxin saporin-mAB 73

Current Eye Research

Volumn 24, Issue 1, 2002, Pages 58-65

  Campos, Emilio C ^a   Schiavi, Costantino ^a   Bolognesi, Andrea ^a   Bellusci, Costantino ^a   Lubelli, Chiara ^a   Duca, Alberta ^a   Polito, Letizia ^a   Poulas, Konstantinos ^a   Tzartos, Socrates J ^a   Stirpe, Fiorenzo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Botulinum toxin; Extraocular muscles; Immunotoxin; Rabbit; Saporin

Indexed keywords

CHOLINERGIC RECEPTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RIBOSOME INACTIVATING PROTEIN; SAPORIN; SAPORIN MONOCLONAL ANTIBODY 73; UNCLASSIFIED DRUG; GLYCOSIDASE; PROTEIN SYNTHESIS INHIBITOR; RIP PROTEIN, SAPONARIA OFFICINALIS; VEGETABLE PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; EXTRAOCULAR MUSCLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATION; INOCULATION; MACROPHAGE; MICROSCOPY; MUSCLE INJURY; NECROSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RABBIT; SAFETY; ANIMAL; BIOPSY; CELL CULTURE; IMMUNOLOGY; INJECTION; PATHOLOGY;

ANIMAL; ANTIBODIES, MONOCLONAL; APOPTOSIS; BIOPSY; FEMALE; HUMAN; IMMUNOTOXINS; INJECTIONS; NECROSIS; OCULOMOTOR MUSCLES; PLANT PROTEINS; PROTEIN SYNTHESIS INHIBITORS; RABBITS; RECEPTORS, CHOLINERGIC; SAFETY; TUMOR CELLS, CULTURED; ANIMALS; HUMANS; N-GLYCOSYL HYDROLASES;

EID: 0035996284     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.24.1.58.5430     Document Type: Article

References (49)

1. Pharmacologic weakening of extraocular muscles
2. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery
3. Botulinum toxin injection in the management of lateral rectus paresis
4. Combined botulinum toxin chemodenervation and surgery
5. Botulinum injection treatment for endocrine orbital myopathy
6. Botulinum treatment of strabismus following retinal detachment surgery
7. Treatment of acquired nystagmus with botulinum toxin
8. La tossina botulinica come terapia del blefarospasmo essenziale e come alternativa alla chirurgia dello strabismo
9. Effect of injection sites of botulinum toxin for blepharospam treatment: Statistical analysis
10. New indications for botulinum toxin A in strabismus and in medical treatment of amblyopia: Editorial review
11. Botulinum toxin in essential infantile esotropia and in Lang's normosensorial strabismus
12. Development of binocular motion processing following botulinum injection in infantile esotropia
13. Observations on bilateral simultaneous Botulinum toxin injection in infantile esotropia
14. Botulinum toxin management of essential infantile esotropia in children
15. Critical age of botulinum toxin treatment in essential infantile esotropia
16. Chemodenervation of strabismic children: A 2 to 5 years follow-up study compared with shorter follow-up
17. Response and immunoresistance to botulinum toxin injections
18. Serum antibody production to botulinum A toxin
19. Doxorubicin does not spread systematically following a local injection into the eyelids of rabbis
20. Doxorubicin chemomyectomy in orbicularis oculi: Increasing drug infiltration at the injection site
21. Clinical doxorubicin chemomyectomy: An experimental treatment for benign essential blepharospasm and hemifacial spasm
22. Long-term efficacy of local doxorubicin chemomyectomy in patients with ble-pharospasm and hemifacial spasm
23. Doxorubicin chemomyectomy is enhanced when performed two days following bupivacaine injections: The effect coincides with the peak of muscle satellite cell division
24. Direct injection of liposome-encapsulated doxorubicin optimizes chemomyectomy in rabbit eyelid
25. Cyclosporin protects the eyelid skin from injury after injection of doxorubicin
26. Local injections of corticotropin relasing factor reduce doxorubicin-induced acute inflammation of the eyelid
27. Immunotoxins for targeted cancer therapy
28. Are immunoconjugates useful for therapy with autoimmune diseases?
29. Selective elimination of fibroblasts from pancreatic islets monolayers by basic fibroblast growth factor-saporin mitotoxin
30. Rationale for the use of immunotoxins in the treatment of HIV-infected humans
31. Resolution of cutaneous inflammation after local elimination of macrophages
32. Skeletal muscle-specific immunotoxin for the treatment of focal muscle spasm
33. Acute effects of the skeletal muscle-specific immunotoxin ricin-mAb 35 on extraocular muscles of rabbits
34. Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis
35. Isolated ricin B-chain-mediated apoptosis in U937 cells
36. Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus) and from the latex of Hura crepitans L. (sandbox tree)
37. Mechanisms of action of ricin and related toxins on the inactivation of ribosomes
38. Saporin immunotoxins
39. Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma. In vitro evaluation
40. Large scale chromatographic purification of ribosome-inactivating proteins
41. Characterization of monoclonal antibodies to denaturated Torpedo and to native calf acetylcholine receptors: Species, subunit and region specificity
42. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis: An Fab monoclonal antibody protects against antigenic modulation by human sera
43. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins
44. Purification and partial characterization of single-chain ribosome-inactivating proteins from the seeds of Phytolacca dioica L.
45. Synthesis of hemoglobin in a cell free system: Properties of the complete system
46. Botulinum toxin treatment in the facial muscles of humans: Evidence of an action in untreated near muscles by peripheral local diffusion
47. Ricin induces the production of tumour necrosis factor-α and interleukin-1β by human peripheral blood mononuclear cells